New vaccine trial aims to stop parasitic worm infection in its tracks
NCT ID NCT03910972
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new vaccine (Sm-TSP-2) to protect against intestinal schistosomiasis, a parasitic worm infection common in parts of Africa. Healthy adults in Uganda received different doses of the vaccine, with or without an immune booster, to check safety and how well it triggers protection. The goal is to see if the vaccine can reduce or prevent infection.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCHISTOSOMA MANSONI are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Makerere University Walter Reed Project
Kampala, Uganda
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can extra doses of an old drug reverse liver scarring?
- Heart-Lung connection may explain survival advantage in Parasite-Linked hypertension
- Can mapping migrant networks help end neglected tropical diseases?
- Higher dose of schistosomiasis drug shows promise for toddlers
- New study tracks hidden infections in migrants
- Egyptian schistosomiasis study launches to map disease hotspots